The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN
Open accessAbstract
Patients afflicted with pancreatic ductal adenocarcinoma (PDAC) face a dismal prognosis, but headway could be made if physicians could identify the disease earlier. A compelling strategy to broaden the use of surveillance for PDAC is to incorporate molecular biomarkers in combination with clinical analysis and imaging tools. This article summarizes the components involved in accomplishing biomarker validation and an analysis of the requirements of molecular biomarkers for disease surveillance. We highlight the significance of consortia for this research and highlight resources and infrastructure of the Early Detection Research Network (EDRN). The EDRN brings together the multifaceted expertise and resources needed for biomarker validation, such as study design, clinical care, biospecimen collection and handling, molecular technologies, and biostatistical analysis, and studies coming out of the EDRN have yielded biomarkers that are moving forward in validation. We close the article with an overview of the current investigational biomarkers, an analysis of their performance relative to the established benchmarks, and an outlook on the current needs in the field. The outlook for improving the early detection of PDAC looks promising, and the pace of further research should be quickened through the resources and expertise of the EDRN and other consortia. See all articles in this CEBP Focus section, “NCI Early Detection Research Network: Making Cancer Detection Possible.”
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Such biomarker “panels” often build upon CA 19-9 and demonstrate improved performance in early-stage disease compared with CA 19-9 alone.40–43”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas
Tanaka, M., Fernández-del Castillo, C., Kamisawa, T., Jang, J. Y., Levy, P., Ohtsuka, T., Salvia, R., Shimizu, Y., Tada, M., & Wolfgang, C. L. (2017) · Pancreatology · doi:10.1016/j.pan.2017.07.007 · Cited by 1,797
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
European evidence-based guidelines on pancreatic cystic neoplasms
The European Study Group on Cystic Tumours of the Pancreas (2018) · Gut · doi:10.1136/gutjnl-2018-316027 · Cited by 1,417
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study
Brugge, W. R., Lewandrowski, K. B., Lee-Lewandrowski, E., Centeno, B. A., Szydlo, T. E., Regan, S., del Castillo, C. F., & Warshaw, A. L. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.013 · Cited by 1,382
Vege, S. S., Ziring, B., Jain, R., Moayyedi, P., Adams, M. A., Dorn, S. D., Dudley-Brown, S. L., Flamm, S. L., Gellad, Z. F., Gruss, C. B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.015 · Cited by 1,138
Flagged first, then by citations
1 of the 83 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Self-citationArtificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158
Self-citationHaab, B. B., Qian, L., Staal, B., Jain, M., Fahrmann, J. F., Worthington, C., Prosser, D., Velokokhatnaya, L., Lopez, C., Tang, R., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217245 · Cited by 32
Self-citationMahajan, U. M., Oehrle, B., Goni, E., Strobel, O., Kaiser, J., Grützmann, R., Werner, J., Friess, H., Gress, T. M., Seufferlein, T., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00056-1 · Cited by 24
Challenges of early detection of pancreatic cancer
Shen, M. J., Jamali, A., & Katona, B. W. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191942 · Cited by 24
“A tiered approach to screening has been posited by groups such as the Early Detection Research Network (127, 128).”
Metadata
- Authors
- Liu, Y., Kaur, S., Huang, Y., Fahrmann, J. F., Rinaudo, J. A., Hanash, S. M., Batra, S. K., Singhi, A. D., Brand, R. E., Maitra, A., & Haab, B. B.
- Affiliations
- Van Andel Institute (US)
- Nebraska Medical Center (US)
- Fred Hutch Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- National Cancer Institute (US)
- University of Pittsburgh Medical Center (US)
- ORCID
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2020-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2513-2523
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- PMC
- PMC7710622
- OpenAlex
- W3035524190
- Cited by
- 17
- References
- 83
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 1
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NCI
- Early Detection Research Network (U01 CA152653)
- Alliance of Glycobiologists for Cancer Detection (U01 CA226158, U01 CA200468, U01 CA196403, R01 CA218004, P50 CA221707)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, early cancer detection, molecular biomarkers, biomarker validation, Early Detection Research Network, cancer surveillance, research consortium, biospecimen collection
- MeSH terms
- Aged, Female, Humans, Male, Pancreatic Neoplasms, Biomarkers, Tumor, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
